
- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
An insecticide created by humans is chlorantraniliprole. It belongs to the group of pesticides known as anthranilic diamides.
In addition to some beetles and "real" bugs like aphids and spittlebugs, it also manages caterpillars or larvae of moths and butterflies. For usage on a range of fruits, vegetables, potatoes, and rice, products containing chlorantraniliprole may be labelled.
Additionally, they are utilised as seed treatments and on cotton, turf grass, decorative plants, and public landscaped areas.
The toxicity of chlorantraniliprole to humans and other mammals is quite low. Skin irritation is not caused by chlorantraniliprole. The eyes may feel a little irritated. It won't cause skin sensitivity.
Chlorantraniliprole has a very low level of toxicity when consumed. A person's cardiac function was abnormal after consuming a product containing chlorantraniliprole. In rabbits, chlorantraniliprole briefly irritated their eyes, but all symptoms vanished after 72 hours.
The Global Chlorantraniliprole insecticide market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Under the brand names Natvol (Technical: Chlorantraniliprole 8.8% + Thiamethoxam 17.5% SC) and Natligo (Technical: Chlorantraniliprole 9.3% + Lambda-cyhalothrin 4.6% ZC), Natco Pharma Limited has introduced two chlorantraniliprole (CTPR) pesticide-formulated combination products.
The development of two new CTPR-based formulations, CITIGEN and VISTARA, has been announced by Best Agrolife Ltd., a significant player in the Indian agricultural inputs sector.
Millions of individuals worldwide have been infected with COVID-19 disease, and major nations throughout the world have enacted work stoppage orders and foot prohibitions as a result of the disease's global spread.
Most industries, including those involving chlorantraniliprole insecticide, have been significantly damaged, with the exception of those involving medical supplies and life support items.
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
21 | Product installation rate by OEM, 2023 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2023 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |